INTRODUCTION
The major apoproteins of plasma lipoproteinis have been extensively studied (1, 2) . In addition to transporting insoluble lipids in body fluids, apoproteins have important roles in lipoprotein metabolismn. Apoproteins function as cofactors for enzymes (3, 4) , biind to cell surface receptors (5, 6) , regulate intracellular cholesterol content (5, 7) , and have an importaint role in the secretion of lipoproteins (8) .
Recently the role of the intestine has been explored as a site of synthesis of apoproteins. These studies have revealed that human intestinal epitheliumn contains apolipoprotein B (apoB)l (8, 9) , apoA-I, and apoA-II (10, 11) and in vitro isotopic incorporation studies have demonstrated synthesis of these apoproteins (11) . Quantitation of apoA-I and apoA-II output in the chylous urine of two subjects with chvluria revealed that the intestine is a major source of these apoproteins for plasma (12) .
Several "new" human apoproteins have recently been described. These include apoD (13) , apoF (14) , and the threonine-poor apoproteins (15) . During studies of intestinal lipoproteins performed on two subjects with chyluria resulting from mesenteric lymphatic-urinary fistulae, we noted an apoprotein that was a component of intestinal triglyceride-rich lipoproteins, chylomicrons, and very low density lipoproteins (VLDL) (12) . This apoprotein is analogous to a similar rat chylomicron and high density lipoprotein (HDL) apoprotein, apoA-IV (16, 17) . Human apoA-IV has been recently described as a component of thoracic duct triglyceride-rich lipoproteins (18) and in plasma chylomicrons from nonfasting hypertriglyceridemic subjects (19) . These studies revealed apoA-IV is an immunologically distinct apoprotein with 46,000 mol wt (12, 18, 19) . We have extended our studies of apoA-IV and demonstrated that human intestinal epithelial cells contain apo-IV and the content increases with lipid absorption consistent with local synthesis. ApoA-IV is transported on chylomicrons and intestinal VLDL and is found in plasma of normal subjects mainly free, unassociated with lipoproteins.
METHODS
Subjects and collection of samples. The subjects with chyluria have been described previously (12) . Urine was collected from one subject at 3-h intervals after the ingestion of 40 g of corn oil. Sodium azide was added and the samples refrigerated immediately. Aliquots of whole urine were stored at -800C for apoprotein quantitation. Lipoproteins (chylomicrons, VLDL, and HDL) were isolated from freshly collected samples from both chyluric subjects.
Thoracic duct lymph was collected from a child who had undergone cardiac surgery and had developed a postoperative thoracic duct fistula. The fluid drained continuously from an intrathoracic drainage tube and became milky soon after the ingestion of lipid. Lipoproteins were isolated from the freshly collected fluid.
Blood was collected in the presence of EDTA from five normal male volunteers who had fasted for 18 h and again 2 h after the ingestion of one pint of commercially obtained heavy cream Aliquots of unpurified lipoprotein fractions were saved for apoprotein quantification. After initial isolation, chylomicrons and VLDL were purified by passage through 2% agarose (Biogel A-50M, Bio-Rad Laboratories, Richmond, Calif.) (22) . LDL and HDL were purified by recentrifugation at the upper density limit. Lipoproteins were dialyzed against saline to remove the high salt concentration.
Polyacrylamide gel electrophoresis. Purified lipoproteins were delipidated in ethanol ether (3:2 vol/vol) at 4°C overnight and washed twice with ether. Delipidated apoproteins (20 ,ug) were subjected to sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (5.6% gels) in the presence of dithiothreitol as described previously (22) . The gels were stained with Coomassie blue. Apoproteins were quantitated densitometrically (22) and were identified by their electrophoretic mobility as compared with purified apoproteins subjected to simultaneous gel electrophoresis. The relative chromogenicity of apoA-I and apoA-IV was determined by subjecting 1-10 ug of each apoprotein to SDS gel electrophoresis. The SDS gels were scanned densitometrically and the area under the absorbance tracing quantitated by planimetry. To assess the effect of varying the amount of total protein, 8-30 ,g of total chylomicron protein was applied to SDS gels. The percentage distribution of apoproteins remained linear throughout this range of protein.
Isolation of apoA-IV. ApoA-IV was isolated from purified urinary chylomicrons obtained from a chyluric subject. Preparative gel electrophoresis (Polyprep 100, Buchler Instruments, Div. Searle Diagnostics, Inc., Fort Lee, N. J.) was performed using 5.6% polyacrylamide gel in SDS as described previously (12) . Delipidated chylomicron apoproteins were solubilized in 0.2 M Tris buffer, pH 7.2 containing 0.1 M decyl sulphate and 40 mM dithiothreitol before application to the preparative gel. The eluted gel fractions were monitored by analytical SDS gel electrophoresis. The fractions containing pure apoA-IV by SDS gel electrophoresis were extensively dialyzed against 0.05 M NH4 HCO3, pH 8, and stored at -20C. Purified apoA-IV did not react with antisera to apoA-I, apoA-II, apoE, or apoB.
Preparation of antisera to apoA-IV. Antisera to apoA-IV were prepared by immunizing rabbits with unfixed and unstained polyacrylamide gel slices of chylomicron apoproteins (23) . ApoA-IV was located by its relative mobility as determined on duplicate stained gels scanned densitometrically. Individual gel slices were homogenized, mixed with an equal volume of complete Freund's adjuvant and injected subcutaneously into New Zealand rabbits. The antiserum was characterized by immunodiffusion and immunoelectrophoresis. There was no reaction against purified apoA-I, apoA-II, apoE, or albumin. A single arc of identity was formed against whole serum and purified apoA-IV indicating the antiserum was monospecific.
Immunofluorescentce studies on isolated intestinal epithelial cells. Peroral intestinal biopsies were obtained from four normal volunteers aged between 20 and 35 yr. Informed consent was obtained from each subject.
Small-bowel biopsies were performed using a four-port multipurpose Rubin intestinal biopsy tube (Quinton Instruments, Seattle, Wash.). Biopsies were taken from the duodenojejunal junction after an overnight fast. A repeat biopsy was performed 45 min after 100 ml of heavy cream was instilled into the stomach.
Intestinal epithelial cells were then isolated from the biopsies and indirect immunofluorescence studies performed using antiserum to apoA-IV as previously described (10, 23) . Nonimmune rabbit serum and antiserum that had been absorbed with purified apoA-IV served as controls. Two observers examined 10 slides from each of the four biopsies. Slides were photographed with Agfachrome 64 film (Eastman Kodak Co., Rochester, N. Y.) with a x40 oil immersion objective.
Quantitative immunoelectrophoresis ofapoA-IV. Quantitation of apoA-IV was performed using the rocket technique of Laurell (24) . Electrophoresis was performed using a water cooled electrophoresis apparatus (MRA Corp., Clearwater, Fla.) with a 0.05-M barbital buffer, pH 8.8. The procedure used was similar to that described previously for apoA-I (10). Antiserum was mixed with 1% agarose in 0.05 M barbital buffer, pH 8.8 in a final concentration of 5%, and 2 ,ul of sample or standard was applied to each well. In this assay, normal serum gave an identical rocket height if it was: Colu inii chromaitography. Column chromatography of whole plasma in 10% agarose (Biogel A 50M, 100-200 mesh) was performed with two 120 x 1.0-cm columns run in series. The columns were eluted using NaCl-EDTA buffer at 4°C at a flow rate of 2.5 ml/h. Sample volumes of 0.5 ml were applied to the column. The column was calibrated with plasma LDL and HDL. ApoA-I and apoB were detected in column fractions by Ouchterlony immunodiffusion. Fractions were pooled, dialyzed against water, and lyophilized. The lyophilized fractions were delipidated in chloroform:methanol and washed twice in ether. The delipidated fractions were dissolved in small volumes of Tris/urea buffer and subjected to rocket immunoelectrophoresis in order to quantitate apoA-IV. The chloroform: methanol lipid extract was subject to thin-layer chromatography to detect the presence of lipid (25, 26) .
Triglyceride and cholesterol were determined by the autoanalyzer technique (27) and proteins by the method of Lowrv et al. (28) . RESULTS SDS gel electrophoresis. Chylomicrons, VLDL, and HDL were isolated from thoracic duct lymph and chylous urine and purified as described in Methods. The SDS gels of the thoracic duct lipoproteins are shown in Fig. 1 . The lipoproteins from chylous urine had a similar gel pattern (Fig. 4) (12) . The distribution of apoproteins was assessed by planimetry of SDS gels and is shown in Table I . The values represent the percentage distribution of area under the absorbance tracing. Studies performed to assess the relative chromagenicity of apoA-I and apoA-IV revealed that the area under the absorbance tracing for each protein was linear between 1 and 10 ,ug of protein. The relative chromagenicity of apoA-I and apoA-IV did not differ by >10% over this range of protein. Chylomicrons and VLDL from both sources contained similar apoproteins including apoB, apoA-IV, apoE, apoA-I, apoC, and apoA-II. The C proteins and apoA-II migrate together in this reduced gel system, however, apoA-IL was detected immunologically in chylomicrons and VLDL
CHYLOS VLDL HDL FIGURE 1 SDS gels of thoracic duct lymph lipoproteins. Chylomicrons, VLDL, and HDL were isolated from fatty lymph and purified as in Methods. Apoprotein bands are labeled. The ink marker indicating the electrophoresis front is seen at the bottom of the gel.
from both sources. ApoA-IV comprised 10-13% of chylomicron protein and a greater percentage (24% and 30%) of urinary VLDL and thoracic duct VLDL, respectively. The chylomicrons and VLDL were generally free of albumin by Ouchterlony analysis using antisera to human albumin. Unidentified protein bands of higher molecular weight were also present. A major band of Rf = 0.35 (-100,000 mol wt) was noted in chylomicrons and VLDL from thoracic duct lymph. This protein was noted previously in chylomicrons from chylous urine (12) and has not been further identified. The gels of HDL from both sources contained no detectable apoA-IV. linmunofluorescence. Intestinal biopsies were obtained from four volunteers after an overnight fast and again 45 min after cream was instilled into the stomach. Four biopsies were taken on each occasion. Intestinal epithelial cells were isolated from each biopsy. Cells prepared from fasting biopsies demonstrated limited immunofluorescence consistent with the presence of only small amounts of intracellular apoA-IV (Fig. 2,  left) . 45 min after the ingestion of cream, apoA-IV fluorescence in the apical portion of cells markedly increased, suggesting an increase in apoA-IV content during fat absorption (Fig. 2, right) . All fluorescence was blocked by prior absorption of the antiserum with purified apoA-IV. Identical results were obtained in each of four normal subjects.
Electroimmunoassay of apoA-IV. To quantitate apoA-IV an electroimmunoassay was developed. All samples were totally delipidated for this assay. Dilutions of normal sera gave a linear response when run in the assay. The apoA-IV standard was linear between 0.75 mg/dl and 8 mg/dl (r = 0.9992). The lowest point of linearity corresponded to 15 ng of standard 18.5+0.71
Blood was drawn from five fasting normal volunteers and again after the ingestion of one pint of cream. Triglyceride, cholesterol, and apoA-IV were quantified as in Methods. * Mean+SEM (n = 5).
t By paired t test P < 0.01.
Human Apolipoprotein A-IV: Origin and Plasma Distribution total plasma apoA-IV. This small amount appears to be associated with the lipoprotein and not present as a result of contamination with small amounts of the d > 1.21-g/ml fraction as small amounts of apoA-IV were detected immunologically in purified (recentrifuged) HDL. ApoA-IV only accounted for 0.05% (0.05+0.01%, n = 4) of purified HDL protein.
The occurrence of apoA-IV in the d > 1.21 fraction of serum might be the result of ultracentrifugation or due to the apoprotein existing free in plasma. To further explore this possibility, immunoelectrophore- Whole fasting plasma from one subject was fractionated by agarose column chromatography using 10% agarose. The elution profile is shown in Fig. 5 . ApoB and apoA-I were detected in the column fractions by Ouchterlony immunodiffusion. The elution volumes of LDL and HDL are shown. These elution volumes corresponded with the localization of apoB and apoA-I. Pooled fractions were dialyzed, lyophilized, delipidated, and solubilized in Tris-urea buffer for immunoassay for apoA-IV. The majority (77%) of apoA-IV was present in the fractions that eluted after HDL. This fraction contained only small amounts ofphospholipid. Total recovery of apoA-IV from the column was 85% of that applied.
DISCUSSION
ApoA-IV is an immunologically distinct human apoprotein analogous to a similar rat apoprotein. Studies in the rat have demonstrated synthesis of apoA-IV by the intestine (30, 31) and to a lesser extent by the liver (32) . In rat mesenteric lymph apoA-IV is found as a chylomicron, intestinal VLDL, and HDL apoprotein (31, 33) , as well as free in the d > 1.21-g/ml fraction (31) . In rat plasma, apoA-IV is found in both the HDL and d > 1.21 fraction (16, 17, 34) and is possibly transferred from the chylomicron surface, together with phospholipid and apoA-I into HDL during chylomicron metabolism (35) .
ApoA-IV has been isolated from intestinal triglyceride-rich lipoproteins obtained from chylous urine (12) and from human thoracic duct lymph (18) . Characterization has demonstrated that it is an immunologically distinct human apoprotein, with a molecular weight of 46,000. Beisiegel and Utermann (19) isolated apoA-IV from the nonfasting plasma ofseveral hypertriglyceridemic subjects. They demonstrated that apoA-IV was present on plasma chylomicrons, however it was easily lost from the chylomicron surface during ultracentrifugation. It was also found by Ouchterlony immunodiffusion in the d > 1.21-g/ml fraction of plasma.
To explore the role of the human intestine in apoA-IV metabolism we studied lipoproteins from chylous urine, human thoracic duct lymph, and the plasma of normal volunteers during alimentary lipemia. We also performed immunofluorescence studies The findings of limited intracellular fluorescence for apoA-IV in intestinal epithelial cells from fasting subjects and a marked increase in fluorescence during lipid absorption is consistent with synthesis of apoA-IV by the intestine during lipid absorption. This is supported by the marked increase in apoA-IV excreted in the urine of one chyluric subject after lipid ingestion, and the small but statistically significant rise in plasma apoA-IV levels during alimentary lipemia in normal volunteers.
In chylous urine 56% of apoA-IV was associated with triglyceride-rich lipoproteins presumably secreted by the intestine. We cannot be sure of the origin of that present in the d > 1.006 fraction. Some apoA-IV may be present in this fraction as a result of displacement from less dense lipoproteins due to ultracentrifugation. The contribution of free apoA-IV filtered from plasma during lipid absorption is also not known.
To estimate the amount of apoA-IV secreted by the intestine during lipid absorption, calculations based on the extent of the mesenteric lymphatic shunt were performed. In addition it is assumed that only the apoA-IV associated with triglyceride-rich lipoproteins (chylomicrons and intestinal VLDL) was derived from the intestine. These calculations reveal that for 40 g of ingested lipid, 160 mg of apoA-IV was secreted on chylomicrons and intestinal VLDL. We cannot, however, estimate the intestinal contribution of apoA-IV to plasma levels as we do not know the plasma residence time. It is also not known whether the human liver secretes apoA-IV.
ApoA-IV was found in normal plasma in a concentration of 15.7 mg/dl. Using three different techniques the bulk of fasting plasma apoA-IV was found free, unassociated with lipoproteins. Ultracentrifugally, 98% of apoA-IV was found in the d > 1.21-g/ml fraction whereas 77% was found in this fraction using column chromatography. The remainder (27%) eluted with lipoproteins suggesting that small amounts of apoA-IV do exist associated wth lipoproteins. This was confirmed by the findings ofvery small amounts ofapoA-IV in purified plasma HDL (<O.1% of HDL protein) using immunological techniques, despite the absence of apoA-IV on SDS gels. Although the majority of apoA-IV was found in the lipoprotein-free fraction of plasma, the present studies have not determined whether this apoprotein is associated with small amounts of lipid (i.e., phospholipid) or indeed exists in a lipid-free form in plasma. Studies are in progress to more fully characterize the apoA-IV in this fraction.
After the ingestion of lipid, plasmna apoA-IV levels rose by 16%. The rise was seen in each subject studied, indicating that intestinal apoA-IV contributes to plasma levels. Chylomicrons were isolated from plasma by a single ultracentrifugation and purified by agarose column chromatography. SDS gels of chylomicrons from four of the five subjects studied revealed the presence of apoA-IV. The unpurified d < 1.006 fraction (Table III) contained 10% of plasma apoA-IV indicating that in lipemic plasma a significant amount Human Apolipoprotein A-IV: Origin and Plasma Distribution of apoA-IV is still associated with chylomicrons. The bulk (90%) however, was recovered in the d > 1.21 fraction.
These studies are consistent with apoA-IV synthesis in the human intestine and secretion as a chylomicron and intestinal VLDL component. The findings of reduced plasma levels of apoA-IV in four subjects with abetalipoproteinemia who cannot form chylomicrons or VLDL (36, 37) indicate that apoA-IV may be secreted independently of this mechanism. Within plasma, apoA-IV exists associated with plasma chylomicrons, small amounts in other lipoproteins, and the majority free, unassociated with lipoproteins. During in vitro incubation studies using human chylomicrons (12) apoA-IV and apoA-I were transferred from the chylomicron surface when chylomicrons were incubated with plasma or HDL. ApoA-IV was not however, recovered in HDL reisolated from the incubation mixture by ultracentrifugation. These studies suggest that HDL may be involved in the subsequent metabolism of human apoA-IV even though it is not a major HDL apoprotein in normal plasma. It is of interest that apoA-IV levels determined in one patient with Tangier disease (10, 38) were normal (13.6 m0gdl) despite severely reduced HDL and apoA-I levels (10) indicating that apoA-IV does not participate in the abnormal catabolism of chylomicron-HDL apoproteins characteristic of Tangier disease (39, 40) . In addition, we have observed that some subjects with acquired lecithin cholesterol acyltransferase deficiency resulting from alcoholic hepatitis have apoA-IV as an HDL apoprotein (unpublished results) again suggesting that HDL may be involved in apoA-IV metabolism. The present studies have not delineated the mechanisms whereby apoA-IV originating in the intestine is metabolized in the systemic circulation. It is probable that some apoA-IV may transfer from the surface of intestinal lipoproteins to other plasma lipoproteins (e.g., HDL) during lipolysis, along with other chylomicron surface components (35, 41) . Further studies are necessary to determine the role of plasma lipoproteins in apoA-IV metabolism and the factors that determine its ultimate distribution in plasma.
